

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 45

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 45

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 45

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

Latin, English, French, Spanish:

Recommended INN Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

adekalantum

adekalant

tert-butyl 7-[(*S*)-3-(*p*-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1] nonane-3-carboxylate


adékalant

7-[(2*S*)-3-(4-cyanophénoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1] nonane-3-carboxylate de 1,1-diméthyléthyle

adekalant

7-[(*S*)-3-(*p*-cianofenoxi)-2-hidroxipropil]-3,7-diazabicyclo[3.3.1]nonano-3-carboxilato de *terc*-butilo

C₂₂H₃₁N₃O₄



alemtuzumabum

alemtuzumab

immunoglobulin G 1 (human-rat monoclonal CAMPATH-1H γ 1-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer

alemtuzumab

immunoglobuline G1 anti-(antigène CD52 humain) (chaîne γ 1 de l'anticorps monoclonal de rat CAMPATH-1H humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat CAMPATH-1H humanisé

alemtuzumab

inmunoglobulina G 1 anti-(antígeno humano CD52) (cadena γ 1 del anticuerpo monoclonal hombre-rata CAMPATH-1H), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal hombre-rata CAMPATH-1H

aliskirenum


aliskiren

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

aliskirène

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(3-amino-2,2-diméthyl-3-oxopropyl)-4-hydroxy-7-[4-méthoxy-3-(3-méthoxypropoxy)benzyl]-8-méthyl-2-(1-méthyléthyl)=nonanamide

aliskireno

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(2-carbamoil-2-metilpropil)-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi)encil]-8-metilnonanamidaC₃₀H₅₃N₃O₆**amiloxatum**


amiloxate

isopentyl *p*-methoxycinnamate

amiloxate

(E)-3-(4-méthoxyphényl)prop-2-énoate de 3-méthylbutyle

amiloxato

p-metoxicinamato de isopentiloC₁₅H₂₀O₃**bevacizumabum**

bevacizumab

immunoglobulin G 1 (human-mouse monoclonal rhuMAb-VEGF γ -chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer

bévacizumab

immunoglobuline G1 anti-(facteur de croissance de l'endothélium vasculaire humain) (chaîne γ 1 de l'anticorps monoclonal de souris rhuMAb-VEGF humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris rhuMAb-VEGF humanisé

bevazizumab

inmunoglobulina G 1 anti-(factor de crecimiento del endotelio vascular humano) (cadena γ 1 del anticuerpo monoclonal hombre ratón rhuMAb-VEGF), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal hombre-ratón rhuMAb-VEGFC₆₆₃₈H₁₀₁₆₀N₁₇₂₀O₂₁₀₈S₄₄

biotinum


biotin

5-[(3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl]pentanoic acid

biotine

acide 5-[(3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thiéno[3,4-*d*]imidazol-4-yl]pentanoïque

biotina

ácido 5-[(3*a*S,4*S*,6*a*R)-2-oxohexahidro-1*H*-tieno[3,4-*d*]imidazol-4-il]pentanoico $C_{10}H_{16}N_2O_3S$ **bivatuzumabum**

bivatuzumab

immunoglobulin G 1 (human-mouse monoclonal BIWA4 γ 1-chain anti-human antigen CD44v8), disulfide with human-mouse monoclonal BIWA4 κ -chain, dimer

bivatuzumab

immunoglobuline G1 anti-(antigène CD44v8 humain) (chaîne γ 1 de l'anticorps monoclonal de souris BIWA4 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BIWA4 humanisé

bivatuzumab

immunoglobulina G 1 anti-(antígeno humano CD44v8) cadena γ 1 del anticuerpo monoclonal hombre-ratón BIWA4), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón BIWA4**capravirinum**

capravirine


5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester)

capravirine

carbamate de [5-[(3,5-dichlorophényl)sulfanyl]-4-(1-méthyléthyl)-1-(pyridin-4-ylméthyl)-1*H*-imidazol-2-yl]méthyle

capavirina

carbamato (éster)de 5-[(3,5-diclorofenil)tio]-4-isopropil-1-(4-piridilmetil)imidazol-2-metanol

 $C_{20}H_{20}Cl_2N_4O_2S$ 

capromorelinum


capromorelin

2-amino-*N*-[(1*R*)-1-[[[(3*aR*)-3*a*-benzyl-2,3,3*a*,4,6,7-hexahydro-2-methyl-3-oxo-5*H*-pyrazolo[4,3-*c*]pyridin-5-yl]carbonyl]-2-(benzyloxy)ethyl]-2-methylpropanamide

capromoréline

2-amino-*N*-[(1*R*)-2-[(3*aR*)-3*a*-benzyl-2-méthyl-3-oxo-2,3,3*a*,4,6,7-hexahydro-5*H*-pyrazolo[4,3-*c*]pyridin-5-yl]-1-[(benzyloxy)méthyl]-2-oxoéthyl]-2-méthylpropanamide

capromorelina

2-amino-*N*-[(1*R*)-1-[[[(3*aR*)-3*a*-bencil-2,3,3*a*,4,6,7-hexahidro-2-metil-3-oxo-5*H*-pirazolo[4,3-*c*]piridin-5-il]carbonil]-2-(benciloxi)etil]-2-metilpropionamida $C_{28}H_{35}N_5O_4$ **cridanimodum**

cridanimod


9-oxo-10-acridanacetic acid

cridanimod

acide (9-oxoacridin-10(9*H*)-yl)acétique

cridanimod

ácido 9-oxo-10-acridanacético

 $C_{15}H_{11}NO_3$ **doripenemum**

doripenem



(+)-(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3*S*,5*S*)-5-[(sulfamoylamino)methyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

doripénem

(+)-(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-3-[[[(3*S*,5*S*)-5-[(aminosulfonylamino)méthyl]pyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

doripenem

ácido (+)-(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hidroxietyl]-4-metil-7-oxo-3-[[[(3*S*,5*S*)-5-[(sulfamoiilamino)metil]-3-pirrolidinil]tio]-1-azabicyclo[3.2.0]hept-2-eno-2-carboxílico

**ecraprostum**

ecraprost



butyl (4*R*,5*R*)-2,4-dihydroxy-5-[(1*E*,3*S*)-3-hydroxy-1-octenyl]-1-cyclopentene-1-heptanoate, 2-butyrate

écraprost

7-[(4*R*,5*R*)-2-(butanoyloxy)-4-hydroxy-5-[(1*E*,3*S*)-3-hydroxyoct-1-ényl]cyclopent-1-ényl]heptanoate de butyle

ecraprost

2-butirato de (4*R*,5*R*)-2,4-dihidroxi-5-[(1*E*,3*S*)-3-hidroxi-1-octenil]-1-ciclopenteno-1-heptanoato de butilo

**elarofibanum**

elarofiban



(*S*)-β-[(*R*)-1-[3-(4-piperidyl)propionyl]nipecotamido]-3-pyridinepropionic acid

élarofiban

acide (3*S*)-3-[[[(3*R*)-1-[3-(pipéridin-4-yl)propanoyl]piperidin-3-yl]carbonyl]amino]-3-(pyridin-3-yl)propanoïque

elarofibán

ácido (*S*)-β-[(*R*)-1-[3-(4-piperidil)propionil]nipecotamido]-3-piridinapropiónico



ensulizolum

ensulizole


2-phenyl-5-benzimidazolesulfonic acid

ensulizole

acide 2-phényl-1*H*-benzimidazole-5-sulfonique

ensulizol

ácido 2-fenil-5-benzimidazolsulfónico

 $C_{13}H_{10}N_2O_3S$ **enzacamenum**

enzacamene


(±)-3-(*p*-methylbenzylidene)camphor

enzacamène

(E)-(1*RS*,4*SR*)-1,7,7-triméthyl-3-(4-méthylbenzylidène)bicyclo[2.2.1]heptan-2-one

enzacameno

1,7,7-trimetil-3-(4-metilbencilideno)biciclo[2.2.1]heptan-2-ona

 $C_{18}H_{22}O$ **eptaplatinum**


eptaplatin

cis-[(4*R*,5*R*)-2-isopropyl-1,3-dioxolane-4,5-bis(methylamine)-*N,N'*][malonato(2-)-*O,O'*]platinum

eptaplatine

(SP-4-2)-[[[(4*R*,5*R*)-2-(1-méthyléthyl)-1,3-dioxolane-4,5-diyl]bis(méthanamine)-*N,N'*][propanedioato(2-)-*O,O'*]platine

eptaplatino

cis-[(4*R*,5*R*)-2-isopropil-1,3-dioxolano-4,5-bis(metilamina)-*N,N'*][malonato(2-)-*O,O'*]platino $C_{11}H_{20}N_2O_6Pt$ 

ezetimibum


ezetimibe

(3*R*,4*S*)-1-(*p*-fluorophenyl)-3-[(3*S*)-3-(*p*-fluorophenyl)-3-hydroxypropyl]-4-(*p*-hydroxyphenyl)-2-azetidinone

ézetimibe

(3*R*,4*S*)-1-(4-fluorophényl)-3-[(3*S*)-3-(4-fluorophényl)-3-hydroxypropyl]-4-(4-hydroxyphényl)azétidin-2-one

ezetimiba

(3*R*,4*S*)-1-(*p*-fluorofenil)-3-[(3*S*)-3-(*p*-fluorofenil)-3-hidroxipropil]-4-(*p*-hidroxifenil)-2-azetidinona $C_{24}H_{21}F_2NO_3$ **fondaparinuxum natricum**


fondaparinux sodium

methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O- β -D-glucopyranuronosyl-(1 $\rightarrow$ 4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2-O-sulfo- α -L-idopyranuronosyl-(1 $\rightarrow$ 4)-2-deoxy-6-O-sulfo-2-(sulfoamino)- α -D-glucopyranoside, decasodium salt

fondaparinux sodique

O-6-O-sulfo-2-(sulfoamino)-2-désoxy- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O- β -D-glucopyranuronosyl-(1 $\rightarrow$ 4)-O-3,6-di-O-sulfo-2-(sulfoamino)-2-désoxy- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2-O-sulfo- α -L-idopyranuronosyl-(1 $\rightarrow$ 4)-6-O-sulfo-2-(sulfoamino)-2-désoxy- α -D-glucopyranoside de méthyle décasodique

fondaparinux sódico

sal decasódica del O-2-desoxi-6-O-sulfo-2-(sulfoamino)- α -D-glucopiranosil-(1 $\rightarrow$ 4)-O- β -D-glucopirauronosil-(1 $\rightarrow$ 4)-O-2-desoxi-3,6-di-O-sulfo-2-(sulfoamino)- α -D-glucopiranosil-(1 $\rightarrow$ 4)-O-2-O-sulfo- α -L-idopirauronosil-(1 $\rightarrow$ 4)-2-desoxi-6-O-sulfo-2-(sulfoamino)- α -D-glucopiranósido de metilo $C_{31}H_{43}N_3Na_{10}O_{49}S_8$ 

fosamprenavirum


fosamprenavir

(3*S*)-tetrahydro-3-furyl [(α *S*)- α -[(1*R*)-1-hydroxy-2-(*N*¹-isobutylsulfanilamido)=ethyl] phenethyl]carbamate, dihydrogen phosphate (ester)

fosamprénavir

dihydrogénophosphate de (1*R*,2*S*)-1-[[[(4-aminophényl)sulfonyl](2-méthyl=propyl)amino]méthyl]-3-phényl-2-[[[(3*S*)-tétrahydrofuran-3-yl]oxy]=carbonyl]amino] propyle

fosamprenavir

dihidrógenofosfato (éster) de [(α *S*)- α -[(1*R*)-1-hidroxi-2-(*N*¹-isobutilsulfanil=amido)etil]fenetil]carbamat de(3*S*)-tetrahidro-3-furiloC₂₅H₃₆N₃O₉PS**fosfluconazolum**


fosfluconazole

2,4-difluoro- α , α -bis(1*H*-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)

fosfluconazole

dihydrogénophosphate de 1-(2,4-difluorophényl)-2-(1*H*-1,2,4-triazol-1-yl)-1-(1*H*-1,2,4-triazol-1-ylméthyl)éthyle

fosfluconazol

dihidrógenofosfato (éster) de 2,4-difluoro- α , α -bis(1*H*-1,2,4-triazol-1-ilmetil) benciloC₁₃H₁₃F₂N₆O₄P**fosvesetum**

fosveset



N-[2-[bis(carboxymethyl)amino]ethyl]-*N*-[(*R*)-2-[bis(carboxymethyl)amino]-3-hydroxypropyl]glycine, 4,4-diphenylcyclohexyl hydrogen phosphate (ester)

fosvését

acide 2,2'-[[[(1*R*)-1-[[[2-[bis(carboxyméthyl)amino]éthyl](carboxyméthyl)=amino] méthyl]-2-[[[(4,4-diphénylcyclohexyl)oxy]hydroxyphosphoryl]=oxy]éthyl]imino] diacétique

fosveset

4,4-difenilciclohexilhidrógenofosfato (éster) de *N*-[2-[bis(carboximetil)=amino]etil]-*N*-[(*R*)-2-[bis(carboximetil)amino]-3-hidroxiopropil]glicina



gadofosvesetum
gadofosveset


trihydrogen [*N*-[2-[bis(carboxymethyl)amino]ethyl]-*N*-[(*R*)-2-[bis(carboxymethyl)amino]-3-hydroxypropyl]glycine 4,4-diphenylcyclohexyl hydrogen phosphato(6-)]gadolate(3-)

gadofosvészet

trihidrogén[2,2'-[[[(1*R*)-1-[[[2-[bis[(carboxy- κ -*O*)méthyl]amino- κ -*N*]éthyl]=[carboxy- κ -*O*)méthyl]amino- κ -*N*]méthyl]-2-[[[(4,4-diphénylcyclohexyl)oxy]=hydroxyphosphoryl]oxy]éthyl]imino- κ -*N*]diacétato(6-)- κ -*O*-*O*]gadolate(3-)

gadofosveset

[4,4-difenilciclohexilhidrógenofosfato de (6-)-*N*-[2-[bis(carboximetil)amino]=etil]-*N*-[(*R*)-2-[bis(carboximetil)amino]-3-hidroxiopropil]glicina]gadolate(3-) de trihidrógeno



gemtuzumabum
gemtuzumab

immunoglobulin G 4 (human-mouse monoclonal hP67.6 γ 4-chain anti-human antigen CD 33), disulfide with human-mouse monoclonal hP67.6 κ -chain, dimer

gemtuzumab

immunoglobuline G 4 anti-(antigène CD 33 humain) (chaîne γ 4 de l'anticorps monoclonal de souris hP67.6 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris hP67.6 humanisé

gemtuzumab

inmunoglobulina G 4 anti-(antígeno humano CD 33) (cadena γ 4 del anticuerpo monoclonal hP67.6 hombre-ratón), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hP67.6 hombre-ratón

idraparinuxum natricum

idraparinux sodium


methyl O-2,3,4-tri-O-methyl-6-O-sulfo- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2,3-di-O-methyl- β -D-glucopyranuronosyl-(1 $\rightarrow$ 4)-O-2,3,6-tri-O-sulfo- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2,3-di-O-methyl- α -L-idopyranuronosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulfo- α -D-glucopyranoside nonasodium

idraparinux sodique

O-2,3,4-tri-O-méthyl-6-O-sulfo- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2,3-di-O-méthyl- β -D-glucopyranuronosyl-(1 $\rightarrow$ 4)-O-2,3,6-tri-O-sulfo- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2,3-di-O-méthyl- α -L-idopyranuronosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulfo- α -D-glucopyranoside de méthyle nonasodique

idraparinux sódico

O-2,3,4-tri-O-metil-6-O-sulfo- α -D-glucopiranosil-(1 $\rightarrow$ 4)-O-2,3-di-O-metil- β -D-glucopirauronosil-(1 $\rightarrow$ 4)-O-2,3,6-tri-O-sulfo- α -D-glucopiranosil-(1 $\rightarrow$ 4)-O-2,3-di-O-metil- α -L-idopirauronosil-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulfo- α -D-glucopiranosido de metilo nonasódico

 $C_{38}H_{55}Na_9O_{49}S_7$ **isatoribinum**


isatoribine

5-amino-3-(β -D-ribofuranosyl)thiazolo[4,5-*d*]pyrimidine-2,7(3*H*,6*H*)-dione

isatoribine

5-amino-3-(β -D-ribofuranosyl)thiazolo[4,5-*d*]pyrimidine-2,7(3*H*,6*H*)-dione

isatoribina

5-amino-3- β -D-ribofuranosiltiazolo[4,5-*d*]pirimidina-2,7(3*H*,6*H*)-diona $C_{10}H_{12}N_4O_6S$ 

labradimilum

labradimil


*N*²-[(*S*)-2-[L-arginyl-L-prolyl-*trans*-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido]-3-(*p*-methoxyphenyl)propyl]-L-arginine

labradimil

*N*²-[(2*S*)-2-[[L-arginyl-L-prolyl-[(4*R*)-4-hydroxy-L-prolyl]-glycyl-3-(thiophén-2-yl)-L-alanyl]-L-seryl-L-prolyl]amino]-3-(4-méthoxyphényl)propyl]-L-arginine

labradimil

*N*²-[(*S*)-2-[L-arginil-L-prolil-*trans*-4-hidroxi-L-proliilglicil-3-(2-tienil)-L-alanil-L-seril-L-prolinamido]-3-(*p*-metoxifenil)propil]-L-arginina

C₄₉H₇₅N₁₅O₁₂S**ladirubicinum**

ladirubicin


(1*S*,3*S*)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-(1-aziridinyl)-2,3,6-trideoxy-4-*O*-(methylsulfonyl)- α -L-*lyxo*-hexopyranoside

ladirubicine

(7*S*,9*S*)-9-acétyl-7-[[3-(aziridin-1-yl)-4-*O*-(méthylsulfonyl)-2,3,6-tridésoxy- α -L-*lyxo*-hexopyranosyl]oxy]-6,9,11-trihydroxy-7,8,9,10-tétrahydrotétracène-5,12-dione

ladirubicina

(1*S*,3*S*)-3-acetil-1,2,3,4,6,11-hexahidro-3,5,12-trihidroxi-6,11-dioxo-1-naftacenil 3-(1-aziridinil)-2,3,6-tridesoxi-4-*O*-(metilsulfonil)- α -L-*lyxo*-hexopiranósido

C₂₉H₃₁NO₁₁S

lerdelimumabum

lerdelimumab

immunoglobulin G4, anti-(human transforming growth factor b2) (human monoclonal CAT-152 γ 4-chain), disulfide with human monoclonal CAT-152 λ-chain, dimer

lérdelimumab

immunoglobuline G4, anti-(facteur de croissance transformant humain b2) (chaîne γ 4 de l'anticorps monoclonal humain CAT-152), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal humain CAT-152

lerdelimumab

immunoglobulina G4, anti-(factor b2 de crecimiento transformador humano)(cadena γ 4 del anticuerpo monoclonal humano CAT-152), dimero del disulfuro con la cadena λ del anticuerpo monoclonal humano CAT-152

levmetamfetaminum

levmetamfetamine


(-)-(R)-N,α-dimethylphenethylamine

levmétamfétamine

(-)-(2R)-N-méthyl-1-phénylpropan-2-amine

levmetanfetamina

(-)-(R)-N,α-dimetilfenetilamina

C₁₀H₁₅N**lixivaptanum**

lixivaptan


3'-chloro-5-fluoro-4'-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-o-toluanilide

lixivaptan

N-[3-chloro-4-[(5H-pyrrolo[2,1-c][1,4]benzodiazépin-10(11H)-yl)carbonyl]phényl]-5-fluoro-2-méthylbenzamide

lixivaptán

3'-cloro-5-fluoro-4'-(5H-pirrolo[2,1-c][1,4]benzodiazepin-10(11H)-ilcarbonyl)-o-toluanilida

C₂₇H₂₁ClFN₃O₂

melevodopum

melevodopa


(-)-3,4-dihydroxy-L-phenylalanine, methyl ester

mélévodopa

(-)-(2*S*)-2-amino-3-(3,4-dihydroxyphényl)propanoate de méthyle

melevodopa

éster metílico de (-)-3,4-dihidroxi-L-fenilalanina

 $C_{10}H_{13}NO_4$ **meradimatum**


meradimate

p-menth-3-yl anthranilate

méradimate

2-aminobenzoate de 5-méthyl-2-(1-méthyléthyl)cyclohexyle

meradimato

antranilato de *p*-ment-3-ilo $C_{17}H_{25}NO_2$ **norelgestrominum**


norelgestromin

13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one oxime

norelgestromine

13-éthyl-17-hydroxy-18,19-dinor-17 α -prégn-4-én-20-yn-3-one oxime

norelgestromina

13-etil-17-hidroxi-18,19-dinor-17 α -pregn-4-en-20-in-3-ona oxima $C_{21}H_{29}NO_2$ 

octinoxatum


octinoxate

2-ethylhexyl *p*-methoxycinnamate

octinoxate

(E)-3-(4-méthoxyphényl)prop-2-énoate de (2*RS*)-2-éthylhexyle

octinoxato

p-metoxicinamato de 2-etilhexiloC₁₈H₂₆O₃**octisalatum**

octisalate


2-ethylhexyl salicylate

octisalate

2-hydroxybenzoate de (2*RS*)-2-éthylhexyle

octisalato

salicilato de 2-etilhexilo

C₁₅H₂₂O₃**opaviralinum**


opaviraline

isopropyl (S)-2-ethyl-7-fluoro-3,4-dihydro-3-oxo-1(2*H*)-quinoxalinecarboxylate

opaviraline

(2*S*)-2-éthyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2*H*)-carboxylate de 1-méthyléthyle

opaviralina

(S)-2-etil-7-fluoro-3,4-dihidro-3-oxo-1(2*H*)-quinoxalinacarboxilato de isopropiloC₁₄H₁₇FN₂O₃



opebacanum

opebacan	132-L-alanine-1-193-bactericidal/permeability-increasing protein (human)
opébacan	[132-L-alanine]-1-193-protéine humaine augmentant la perméabilité et à action bactéricide
opebacán	132-L-alanina-1-193-proteína(humana) bactericida/incrementadora de la permeabilidad

VNPGVVVRIS	QKGLDYASQQ	GTAALQKELK	RIKIPDYSDS
FKIKHLGKGH	YSFYSM DIRE	FQLPSSQISM	VPNVGLKFSI
SNANIKISGK	WKAQKRFLKM	SGNFDLSIEG	MSISADLKLK
SNPTSGKPTI	TASSCSSHIN	SVHVVHISKSK	VGWLIQLFHK
KIESALRNKM	NSQVCEKVTN	SVSSELQPYF	QTL

oritavancinum

oritavancin	(4'' <i>R</i>)-22- <i>O</i> -(3-amino-2,3,6-trideoxy-3- <i>C</i> -methyl- α -L- <i>arabino</i> -hexopyranosyl)- <i>N</i> ^{6''} -[<i>p</i> -(<i>p</i> -chlorophenyl)benzyl]vancomycin
oritavancine	acide (3 <i>S</i> ,6 <i>R</i> ,7 <i>R</i> ,22 <i>R</i> ,23 <i>S</i> ,26 <i>S</i> ,36 <i>R</i> ,38 <i>aR</i>)-22-(3-amino-3- <i>C</i> -méthyl-2,3,6-tridésoxy- α -L- <i>arabino</i> -hexopyranosyloxy)-3-(2-amino-2-oxoéthyl)-10,19-dichloro-44-[[2- <i>O</i> -[3-[[4'-chlorobiphényl-4-yl)méthyl]amino]-3- <i>C</i> -méthyl-2,3,6-tridésoxy- α -L- <i>arabino</i> -hexopyranosyl]- β -D-glucopyranosyl]oxy]-7,28,30,32-tétrahydroxy-6-[[[(2 <i>R</i>)-4-méthyl-2-(méthylamino) pentanoyl]amino]-2,5,24,38,39-pentaoso-2,3,4,5,6,7,23,24,25,26,36,37,38,38 <i>a</i> -tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22 <i>H</i> -13,16:31,35-diméthéno-1 <i>H</i> ,13 <i>H</i> -[1,6,9]oxadiazacyclohexadécino [4,5- <i>m</i>][10,2,16]benzoxadiazacyclotétracosène-26-carboxylique
oritavancina	(4' <i>R</i>)-22- <i>O</i> -(3-amino-2,3,6-tridesoxi-3- <i>C</i> -metil- α -L- <i>arabino</i> -hexopiranosil)- <i>N</i> ^{6'} -[<i>p</i> -(<i>p</i> -clorofenil)bencil]vancomicina



ozogamicinum
ozogamicin



methyl (1*R*,4*Z*,8*S*,13*E*)-13-[2-[[[*p*-(3-carbamoylpropoxy)- α -methylbenzylidene]hydrazino]carbonyl]-1,1-dimethylethyl]dithio]ethylidene]-8-[[4,6-dideoxy-4-[[[2,6-dideoxy-4-*S*-[4-[(6-deoxy-3-*O*-methyl- α -*L*-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-*o*-toluoyl]-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-2-*O*-[2,4-dideoxy-4-(*N*-ethylacetamido)-3-*O*-methyl- α -*L*-threo-pentopyranosyl]- β -*D*-glucopyranosyl]oxy]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyne-10-carbamate

ozogamicine

[(1*R*,4*Z*,8*S*,13*E*)-8-[[2-*O*-[4-(acétyléthylamino)-3-*O*-méthyl-2,4-didésoxy- α -*L*-thréo-pentopyranosyl]-4-[[[4-*S*-[3-iodo-5,6-diméthoxy-2-méthyl-4-[(3-*O*-méthyl-6-désoxy- α -*L*-mannopyranosyl]oxy]benzoyl]-2,6-didésoxy-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-4,6-didésoxy- β -*D*-glucopyranosyl]oxy]-13-[2-[[[3-[[1-4-(4-amino-4-oxobutoxy)phényl]éthylidène]hydrazino]-1,1-diméthyl-3-oxopropyl]disulfanyl]éthylidène]-1-hydroxy-11-oxobicyclo[7.3.1] tridéca-4,9-diène-2,6-diyne-10-yl]carbamate de méthyle

ozogamicina

(1*R*,4*Z*,8*S*,13*E*)-13-[2-[[[*p*-(3-carbamoylpropoxy)- α -methylbenzylidene]hydrazino]carbonyl]-1,1-dimethylethyl]dithio]ethylidene]-8-[[4,6-dideoxy-4-[[[2,6-dideoxy-4-*S*-[4-[(6-deoxy-3-*O*-methyl- α -*L*-mannopyranosyl]oxy]-3-iodo-5,6-dimethoxy-*o*-toluoyl]-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-2-*O*-[2,4-dideoxy-4-(*N*-ethylacetamido)-3-*O*-methyl- α -*L*-threo-pentopyranosyl]- β -*D*-glucopyranosyl]oxy]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyne-10-carbamate de méthyle

**paliperidonum**

paliperidone



(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

palipéridone

(9*RS*)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)pipéridin-1-yl]éthyl]-9-hydroxy-2-méthyl-6,7,8,9-tétrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

paliperidona

(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino]etil]-6,7,8,9-tetrahydro-9-hidroxi-2-metil-4*H*-pirido[1,2-*a*]pirimidin-4-ona

**pitavastatinum**

pitavastatin


(3*R*,5*S*,6*E*)-7-[2-cyclopropyl-4-(*p*-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid

pitavastatine

acide (6*E*)-(3*R*,5*S*)-7-[2-cyclopropyl-4-(4-fluorophényl)quinoléin-3-yl]-3,5-dihydroxyhept-6-énoïque

pitavastatina

ácido (3*R*,5*S*,6*E*)-7-[2-cicloclopropil-4-(*p*-fluorofenil)-3-quinolil]-3,5-dihidroxi-6-heptenoico

$C_{25}H_{24}FNO_4$ **rimonabantum**


rimonabant

5-(*p*-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-*N*-piperidinopyrazole-3-carboxamide

rimonabant

5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4-méthyl-*N*-(pipéridin-1-yl)-1*H*-pyrazole-3-carboxamide

rimonabant

5-(*p*-clorofenil)-1-(2,4-diclorofenil)-4-metil-*N*-piperidinopirazol-3-carboxamida $C_{22}H_{21}Cl_3N_4O$ **rostaporfineum**

rostaporfine



(OC-6-13)-dichloro[ethyl (18*RS*, 19*SR*)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato (2-)-*N*²³,*N*²⁴,*N*²⁵,*N*²⁶]tin

rostaporfine

(OC-6-13)-dichloro[(2*RS*, 3*SR*)-2,7,12,17-tétraéthyl-3,8,13,18-tétraméthyl-2,3-dihydrocyclopenta[*a*,*f*]porphyrine-2¹-carboxylato(3-)-*N*²¹,*N*²²,*N*²³,*N*²⁴]stannate(2-) d'éthyle

rostaporfina

(OC-6-13)-dicloro[(18*RS*, 19*SR*)-3,4,20,21-tetradeshidro-4,9,14,19-tetraetil-18,19-dihidro-3,8,13,18-tetrametil-20-forbinacarboxilato de etilo (2-)-*N*²³,*N*²⁴,*N*²⁵,*N*²⁶]estaño

**rosuvastatinum**

rosuvastatin


(3*R*,5*S*,6*E*)-7-[4-(*p*-fluorophenyl)-6-isopropyl-2-(*N*-methylmethane sulfonamido)-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid

rosuvastatine

acide (3*R*,5*S*,6*E*)-7-[4-(4-fluorophényl)-6-(1-méthyléthyl)-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-énoïque

rosuvastatina

ácido (3*R*,5*S*,6*E*)-7-[4-(*p*-fluorofenil)-6-isopropil-2-(*N*-metilmetano sulfonamido)-5-pirimidinil]-3,5-dihidroxi-6-heptenoico

**rotigotinum**

rotigotine



(-)-(*S*)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol

rotigotine

(-)-(*S*)-6-[propyl[2-(thiophén-2-yl)éthyl]amino]-5,6,7,8-tétrahydronaphtalén-1-ol

rotigotina

(-)-(*S*)-5,6,7,8-tetrahidro-6-[propil[2-(2-tienil)etil]amino]-1-naftol



ruplizumabum

ruplizumab

immunoglobulin G 1 (human-mouse monoclonal 5c8 γ 1-chain anti-human CD 40 ligand), disulfide with human-mouse monoclonal 5c8 κ -chain, dimer

ruplizumab

immunoglobuline G1 anti-(ligand CD 40 humain) (chaîne γ 1 de l'anticorps monoclonal de souris 5c8 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris 5c8 humanisé

ruplizumab

inmunoglobulina G 1 anti-(ligando CD 40 humano) (cadena γ 1 del anticuerpo monoclonal hombre-ratón 5c8), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón 5c8**sitaxentanum**


sitaxentan

N-(4-chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-*o*-tolyl]acetyl]-3-thiophenesulfonamide

sitaxentan

N-(4-chloro-3-méthylisoxazol-5-yl)-2-[(6-méthyl-1,3-benzodioxol-5-yl)acétyl]thiophène-3-sulfonamide

sitaxentán

N-(4-cloro-3-metil-5-isoxazolil)-2-[[4,5-(metilenodioxo)-*o*-tolil]acetil]-3-tiofenosulfonamida $C_{18}H_{15}ClN_2O_6S_2$ **sulfamazonom**


sulfamazone

(RS)-(1,5-dimethyl-2-phenyl-3-oxo-2,3-dihydro-1*H*-pyrazol-4-yl)[[4-[(6-methoxypyridazin-3-yl)sulfamoyl]phenyl]amino]methanesulfonic acid

sulfamazone

acide (RS)-(1,5-diméthyl-2-phényl-3-oxo-2,3-dihydro-1*H*-pyrazol-4-yl)[[4-[(6-méthoxypyridazin-3-yl)sulfamoyl]phényl]amino]méthanesulfonique

sulfamazona

ácido (RS)-(1,5-dimetil-2-fenil-3-oxo-2,3-dihidro-1*H*-pirazol-4-il)[[4-[(6-metoxipiridazin-3-il)sulfamoil]fenil]amino]metanosulfónico $C_{23}H_{24}N_6O_7S_2$ and enantiomer
et énantiomère
y enantiómero

talaporfinum

talaporfin


N-[[[(2*S*,3*S*)-18-carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinylporphyrin-20-yl]acetyl]-L-aspartic acid

talaporfine

(2*S*)-2-[[[(7*S*,8*S*)-3-carboxy-7-(2-carboxyéthyl)-13-éthényl-18-éthyl-2,8,12,17-tétraméthyl-7,8-dihydroporphyrin-5-yl]acétyl]amino]butanedioïque

talaporfina

N-[[[(2*S*,3*S*)-18-carboxi-2-(2-carboxietil)-13-etil-2,3-dihidro-3,7,12,17-tetrametil-8-vinilporfirin-20-il]acetil]-ácido-L-aspartico

C₃₈H₄₁N₅O₉**ticalopridum**

ticalopride


4-amino-5-chloro-*N*-[(3*S*,4*R*)-3-methoxy-4-piperidyl]-*o*-anisamide

ticalopride

4-amino-5-chloro-2-méthoxy-*N*-[(3*S*,4*R*)-3-méthoxypipéridin-4-yl]benzamide

ticaloprida

4-amino-5-cloro-*N*-[(3*S*,4*R*)-3-metoxi-4-piperidil]-*o*-anisamida

C₁₄H₂₀ClN₃O₃**tolvaptanum**

tolvaptan



(±)-4'-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1*H*-1-benzazepin-1-yl)carbonyl]-*o*-tolu-*m*-toluidide

tolvaptan

N-[4-[[[(5*RS*)-7-chloro-5-hydroxy-2,3,4,5-tétrahydro-1*H*-1-benzazépin-1-yl]carbonyl]-3-méthylphényl]-2-méthylbenzamide

tolvaptán

(±)-4'-[(7-cloro-2,3,4,5-tetrahidro-5-hidroxi-1*H*-1-benzazepin-1-il)carbonil]-*o*-tolu-*m*-toluidida

**vilazodonum**

vilazodone



5-[4-[4-(5-cyanoindol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide

vilazodone

5-[4-[4-(5-cyano-1*H*-indol-3-yl)butyl]pipérazin-1-yl]benzofurane-2-carboxamide

vilazodona

5-[4-[4-(5-cianoindol-3-il)butil]-1-piperazinil]-2-benzofurancarboxamida



AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 14

(*WHO Chronicle*, Vol. 28, No. 10, 1974)

p. 1	<i>delete</i>	<i>insert</i>
	amfebutamonum	bupropionum
	amfebutamone	bupropion

Dénominations communes internationales recommandées (DCI Rec.): Liste 14

(*Chronique OMS*, Vol. 28, No. 10, 1974)

p. 1	<i>supprimer</i>	<i>insérer</i>
	amfebutamonum	bupropionum
	amfébutamone	bupropione

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 14

(*Crónica de la OMS*, Vol. 28, No. 10, 1974)

p. 1	<i>suprimase</i>	<i>insértese</i>
	amfebutamonum	bupropionum
	anfebutamona	bupropión

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30

(*Informacion farmacutica de la OMS*, Vol. 4, No. 3, 1990)

p. 5	<i>suprimase</i>	<i>insértese</i>
	enalquireno	enalkireno

Recommended International Nonproprietary Names (Rec. INN): List 42

Dénominations communes internationales recommandées (DCI Rec.): Liste 42

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42

(*WHO Drug Information*, Vol. 13, No. 3, 1999)

p. 198	<i>delete/supprimer/suprimase</i>	<i>insert/insérer/insértese</i>
	olmesartanum	olmesartanum medoxomilum
	olmesartan	olmesartan medoxomil
	olmésartan	olmésartan médoxomil
	olmesartán	olmesartán medoxmilo

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

- p. 184 **adalimumabum**
adalimumab *sustitúyase la descripción por la siguiente:*
inmunoglobulina G1 (anti-factor α de necrosis tumoral humano) (cadena pesada del anticuerpo monoclonal humano D2E7), dímero del disulfuro con la cadena κ del anticuerpo D2E7 monoclonal humano
- p. 185 **amiglumidum**
amiglumida *sustitúyase la descripción por la siguiente:*
ácido (R)-4-(2-naftamido)-N,N-dipentilglutarámico
- p. 193 **evernimicinum**
evernimicina *sustitúyase la descripción por la siguiente:*
O-2,3,6-tridesoxi-3-C-metil-4-O-metil-3-nitro- α -L-arabino-hexopiranosil-(1 $\rightarrow$ 3)-O-2,6-didesoxi-4-O-(3,5-dicloro-6-metoxi-4,2-cresotoil)- β -D-arabino-hexopiranosil-(1 $\rightarrow$ 4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno-(1 $\rightarrow$ 3-4)-O-6-desoxi-3-C-metil- β -D-manopiranosil-(1 $\rightarrow$ 3)-O-6-desoxi-4-O-metil- β -D-galactopiranosil-(1 $\rightarrow$ 4)-2,6-di-O-metil- β -D-manopiranosido de O-(1R)-2,3-O-metileno-4-O-(6-metil- β -resorciloil)-D-xilopiranosilideno-(1 $\rightarrow$ 3-4)- α -L-lixopiranosilo
- p. 196 **irolfulvenum**
irolfulveno *sustitúyase la descripción por la siguiente:*
(R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilespiro[ciclopropano-1,5'-[5H]inden]-7'(6'H)-ona
- p. 201 **posaconazolum**
posaconazol *sustitúyase la descripción por la siguiente:*
4-[p-[4-[p-[[[(3R,5R)-5-(2,4-difluorofenil)tetrahidro-5-(1H-1,2,4-triazol-1-ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1S,2S)-1-etil-2-hidroxiopropil]- Δ^2 -1,2,4-triazolin-5-ona

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

